Preparation method of M1 macrophage-tumor vaccine

Abstract

The invention relates to a preparation method of an M1 macrophage-tumor vaccine, and belongs to the technical field of tumor immunization therapy. The preparation method comprises the following steps of preparing a tumor cell lysis solution; performing macrophage differentiation culture; performing macrophage M1 polarization induction. The preparation method has the beneficial effects that the M1 macrophage is a main cleaning cell for body pathogenic microorganism and necrotic tissues; an antigen presentation function is realized; a key effect is achieved in the processes of specific immunity response induction and immune adjustment. The M1 macrophage-tumor vaccine is prepared by stimulating the M1 macrophage by necrosis tumor cells; the defects of insufficient surface antigen expression and weak antigen performance of the tumor cells can be overcome; good induction specificity anti-tumor immune response effects can be achieved.

Description

technical field [0001] The invention relates to the technical field of tumor immunotherapy, in particular to a preparation method of an M1 macrophage tumor vaccine. Background technique [0002] It has been confirmed by many studies that specific active immunotherapy has a certain curative effect on tumors. How to prepare tumor vaccines with high antigen expression is the key to improving the curative effect of this therapy. At present, tumor vaccines in the basic and clinical research stages mainly include modified autologous tumor cell vaccines, single protein component tumor vaccines or heat shock protein peptide complex tumor vaccines, and dendritic cell tumor vaccines, such as patent 93112060.8. The modified autologous tumor cell tumor vaccine is to treat tumor cells with appropriate physical and chemical factors to promote the allosteric or coupling of cell surface proteins, or to increase the foreign body of tumor cells by means of virus transfection and transgene, so...

AI Technical Summary

Problems solved by technology

The modified autologous tumor cell tumor vaccine is to treat tumor cells with appropriate physical and chemical factors to promote the allosteric or coupling of cell surface proteins, or to increase the foreign body of tumor cells by means of virus transfection and transgene, so as to improve tumor immunity. Tumor vaccines prepared based on the immunogenicity of tumor cells. Although the tumor cells can increase the antigenicity of tumor cells to a certain extent after treatment, the modification method has not fundamentally changed the expression of MHC1 molecules on the surface of tumor cells. Disadvantages that heterosexual antigens cannot be expressed on the cell surface, the immune response of autologous modified tumor cell vaccines is not strong, and the clinical efficacy is not very satisfactory

[0003] Single-protein tumor vaccines (such as tumor vaccines prepared with MAGE1 and MAGE2 extracted from melanoma cells), these tumor vaccines cannot overcome the heterogeneity of tumors, and the use of such tumor vaccines will only make the immune system respond to solid tumors. The tumor cells expressing the antigen in the tumor will be killed, but the tumor cells not expressing the antigen in the same tumor will not be killed, and the clinical efficacy of the tumor vaccine with a single protein component is not satisfactory.

[0004] Heat shock protein peptide complex tumor vaccine is a tumor vaccine prepared by using heat shock protein peptide complex isolated from tumor cells. The tumor vaccine of this protein component can overcome the limitation of MHC class I molecules and can be used for allogeneic, and It can overcome the heterogeneity of tumors. Experimental studies have shown that this tumor vaccine has a good tumor inhibitory effect, but the preparation cost of this tumor vaccine is very high, and the number of tumor cells is small, which is not convenient for clinical practical application.

[0005] Dendritic cell tumor vaccine (DC cell tumor vaccine) is a tumor vaccine that is currently being studied at home and abroad. DC cell tumor vaccine is a tumor vaccine prepared by mixing dendritic cells with tumor cells or tumor cell contents. Although tumor vaccines can overcome the disadvantages of weak antigenicity of tumor cells and the inapplicability of allogeneic forms, the separation and extraction of heat shock protein-peptide complexes and DC precursor cells is complicated and expensive, and is not suitable for clinical application

Images